Biogen is continuing to thin its pipeline, dropping a phase 2 program acquired in the $7.3 billion Reata Pharmaceuticals buyout and kicking early-stage Alzheimer’s and Parkinson’s prospects ...

A few months later, Biogen brought tofersen back to life with a fresh analysis of data from that trial plus an open-label extension – in an echo of the approach it took with ill-fated Alzheimer ...

Biogen has bagged $250 million to advance a key pipeline prospect. Royalty Pharma is providing the cash to bankroll phase 3 development of a lupus candidate that Biogen has named in a bunch of ...

Biogen and Stoke Therapeutics have signed a partnership agreement to co-develop and sell Stoke’s experimental treatment for Dravet syndrome, a severe form of epilepsy, outside the U.S., the ...

Stoke could get up to $385 million in development and commercial milestone payments, plus potential tiered royalties on zorevunersen sales in Biogen’s territory. Biogen will support zorevunersen ...

Biogen has entered a collaboration with Stoke Therapeutics to develop and and commercialise zorevunersen to treat Dravet syndrome in all territories outside Canada, Mexico and the US. Dravet ...

Forecasts 2025 profit below expectations Signs $250 million deal for lupus drug funding Shares drop more than 6% in early trading Feb 12 (Reuters) - Biogen (BIIB.O), opens new tab on Wednesday ...

Biotech company Biogen (NASDAQ:BIIB) will be announcing earnings results tomorrow morning. Here’s what to look for. Biogen beat analysts’ revenue expectations by 1.2% last quarter, reporting ...

March 11, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase 3 study will evaluate the efficacy and ...

Biogen expects full-year 2025 total revenue to decline by a mid-single digit percentage. The company’s stock was down about 6% at 10 a.m. on Wednesday with shares priced at around $131 apiece.

Following a flurry of activity at this month’s meeting of the European Medicines Agency’s Committee for Medicinal Products ...